FDA
-
-
-
-
-
-
-
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Sangamo BioSciences (SGMO)
-
-
-
-
-
-
-
Sangamo Therapeutics (SGMO) Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
-
-
-
-
-
-
-
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
-
-
-
-
-
-
-
Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate
-
-
-
-
-
-
-
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
Sangamo Therapeutics (SGMO) Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
-
322,095 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

